Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: Thailand Medical News  Jan 18, 2020  4 years, 3 months, 1 day, 14 hours, 18 minutes ago

WARNING: US FDA Issues Statement That Weight-Control Drug Lorcaserin Increases Cancer Risk

WARNING: US FDA Issues Statement That Weight-Control Drug Lorcaserin Increases Cancer Risk
Source: Thailand Medical News  Jan 18, 2020  4 years, 3 months, 1 day, 14 hours, 18 minutes ago
According to the results of a clinical trial assessing the safety of the drug, the U.S. Food and Drug Administration said that the prescription weight control medicine lorcaserin (Belviq, Belviq XR) may increase the risk for cancer.


 
A Staff from the agency told Thailand Medical News, "We cannot conclude that lorcaserin contributes to the cancer risk but "wanted to make the public aware of this potential risk. We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our review."
 
Doctors and health care providers should balance the benefits of taking lorcaserin against the potential risks when deciding whether to prescribe or continue patients on the medication, the FDA advised. It said that patients currently taking lorcaserin should talk to their health care professionals about the potential increased risk for cancer with use of the medication.
 
Belviq or Lorcaserin is approved for use with a reduced-calorie diet and increased physical activity to help weight loss in adults who are obese or are overweight and have weight-related medical problems. Lorcaserin increases feelings of fullness so that people eat less. It is available as a tablet (Belviq) and an extended-release tablet (Belviq XR).
 
The drug Lorcaserin was approved by the FDA in 2012